StreetInsider.com News Articles

Form 8-K Annovis Bio, Inc. For: Jul 07

Fri, 10 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26754824.html

Form 8-K Annovis Bio, Inc. For: Jul 07

Fri, 10 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26754824.html

Roth/MKM Starts Annovis Bio Inc. (ANVS) at Buy

Tue, 07 Jul 2026 16:12:41 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio Inc. (NYSE: ANVS) with a Buy rating.

For an analyst ratings summary and ratings history on Annovis Bio Inc. click here. For more ratings news on Annovis Bio Inc. click here.

Shares of Annovis Bio Inc. closed at $1.97 yesterday.

Annovis Bio completes enrollment of 850 patients in Phase 3 AD trial

Tue, 07 Jul 2026 07:00:25 -0400

Annovis Bio, Inc. (NYSE: ANVS) announced it has completed enrollment in its pivotal Phase 3 clinical trial evaluating buntanetap for early Alzheimer's disease, enrolling 850 patients across 83 clinical sites in the United States, exceeding the company's original enrollment target.

The trial, identified as NCT06709014, is a randomized, placebo-controlled, double-blind study enrolling patients diagnosed with early Alzheimer's disease, defined by a Mini-Mental State Examination score of 20 to 28 and confirmed positive for the blood biomarker pTau217. Participants receive a daily oral dose of 30mg buntanetap. Primary endpoints measure changes in cognition using the ADAS-Cog13 scale and function using the ADCS-iADL

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout

MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout

Annovis Bio names Cheng Fang as chief scientific officer

Wed, 01 Jul 2026 08:02:48 -0400

Annovis Bio, Inc. (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the Malvern, Pennsylvania-based biotechnology company announced.

Dr. Fang joined Annovis in 2021 and most recently served as senior vice president of research and development. In her new role, she will oversee scientific strategy and research operations for the company's Alzheimer's disease and Parkinson's disease programs, including translational science, clinical development, biomarker strategy, and regulatory interactions.

The promotion follows Annovis's advancement of its lead drug candidate, buntanetap, toward top-line data from a pivotal Phase 3 Alzheimer's disease study and a planned New Drug Application submission.

Maria Maccecchini, Ph.D., founder, president,

Annovis Bio names Cheng Fang as chief scientific officer

Wed, 01 Jul 2026 08:02:48 -0400

Annovis Bio, Inc. (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the Malvern, Pennsylvania-based biotechnology company announced.

Maria Maccecchini, Ph.D., founder, president,

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Wed, 01 Jul 2026 08:00:00 -0400

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.

Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interactions. Her promotion

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Wed, 01 Jul 2026 08:00:00 -0400

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Wed, 01 Jul 2026 08:00:00 -0400

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Wed, 01 Jul 2026 08:00:00 -0400

Form 8-K Annovis Bio, Inc. For: Jun 17

Wed, 17 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260617/26660707.html

Form 8-K Annovis Bio, Inc. For: Jun 17

Wed, 17 Jun 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260617/26660707.html

Annovis Bio regains NYSE listing compliance

Tue, 26 May 2026 08:01:09 -0400

Annovis Bio Inc. (NYSE: ANVS) announced it has regained compliance with New York Stock Exchange continued listing standards after falling below required thresholds in 2025.

The biotechnology company received notice from the NYSE on March 26, 2025, that it was not compliant with Section 802.01B of the NYSE Listed Company Manual. The company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equity was also below $50 million.

The NYSE accepted Annovis's plan to regain compliance on June 19, 2025, and granted an 18-month cure period from the original notice date. The company executed

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.

On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Annovis Bio Regains NYSE Listing Compliance

Tue, 26 May 2026 08:00:00 -0400

Form 4 Annovis Bio, Inc. For: May 20 Filed by: Hoffman Michael B

Thu, 21 May 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26537457.html

Form 4 Annovis Bio, Inc. For: May 20 Filed by: Hoffman Michael B

Thu, 21 May 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26537457.html

Form 8-K Annovis Bio, Inc. For: May 20

Wed, 20 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260520/26528580.html

Form 8-K Annovis Bio, Inc. For: May 20

Wed, 20 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260520/26528580.html